<DOC>
	<DOCNO>NCT01503502</DOCNO>
	<brief_summary>It open-label , randomize , multi-center study . The efficacy safety two flumatinib dos , 400 mg daily 600 mg daily , compare imatinib 400 mg daily newly diagnose ( within 6 month ) patient Philadelphia chromosome-positive ( Ph+ ) Chronic Myelogenous Leukemia chronic phase ( CML-CP ) .</brief_summary>
	<brief_title>A Phase II Study Flumatinib Versus Imatinib Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>It open-label , randomize , multi-center study comparison Gleevec flumatinib newly diagnose ( within 6 month ) CML patient Philadelphia chromosome-positive . One hundred fifty adult patient randomize 1:1:1 ratio . The planned dos follow : 400 mg QD ( 50 patient ) flumatinib , 600 mg QD ( 50 patient ) flumatinib , 400 mg QD ( 50 patient ) imatinib . Flumatinib dose , base food effect result , fast condition . Imatinib dose food per package insert . The study consist 2 phase : 6 month core phase 6 month extension phase .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Male female patient ≥ 18 year ≤ 75 year age . 2 . ECOG 0 , 1 , 2 . 3 . Diagnosis chronic myelogenous leukemia chronic phase confirmation Philadelphia chromosome . 4 . Chronic myelogenous leukemia chronic phase patient within first 6 month diagnosis . 5 . Adequate end organ function define : 1 . Total bilirubin &lt; 1.5 x ULN , 2 . SGOT SGPT &lt; 2.5 x ULN , 3 . Creatinine &lt; 1.5 x ULN , 4 . Serum amylase lipase ≤ 1.5 x ULN , 5 . Alkaline phosphatase ≤ 2.5 x ULN unless consider tumor relate . And patient must follow laboratory value ( ≥ LLN ( low limit normal ) correct within normal limit supplement prior first dose study medication . ) : 1 . Potassium ≥ LLN , 2 . Magnesium ≥ LLN , 3 . Phosphorus ≥ LLN , 4 . Total calcium ( correct serum albumin ) ≥ LLN . 6 . Signed informed consent . 1 . Previously document T315I mutation . 2 . Any medical treatment CML prior study entry exception hydroxyurea and/or anagrelide . Treatment tyrosine kinase inhibitor ( ) prior study entry allow . 3 . Treatment investigational agent ( define use accordance approve indication ) within 4 week prior randomization . 4 . Major surgery within 4 week prior randomization recover prior surgery . 5 . Impaired cardiac function include one following : 1 . History unstable angina . 2 . History clinically document myocardial infarction ( last 12 month ) . 3 . LVEF &lt; 45 % institutional low limit normal range ( whichever high ) determine locally read echocardiogram . 4 . Inability determine QT interval ECG . 5 . Complete leave bundle branch block . 6 . Use ventricularpaced pacemaker . 7 . Congenital long QT syndrome know family history long QT syndrome . 8 . History presence clinically significant ventricular , atrial tachyarrhythmias , QTcF &gt; 450 msec male 470 msec female . 6 . Patients active , uncontrolled psychiatric disorder include : psychosis , major depression , bipolar disorder . 7 . Severe uncontrolled medical condition ( i.e . uncontrolled diabetes , active uncontrolled infection ) . 8 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection , gastric bypass surgery ) . 9 . History significant congenital acquire bleed disorder unrelated cancer . 10 . History chronic pancreatitis history acute pancreatitis within 1 year study entry . 11 . Patients another primary malignancy . 12 . Acute chronic uncontrolled liver severe renal disease consider unrelated disease . 13 . Known allergic study drug , include crude drug adjuvant . 14 . Patients actively receive therapy strong CYP3A4 inhibitor , strong CYP3A4 inducer medication potential prolong QT interval treatment either discontinue switched different medication prior start study drug . 15 . Patients : ( ) pregnant , ( b ) breast feeding , ( c ) childbearing potential without negative pregnancy test within 7 day prior Day 1 study ( ) female childbearing potential unwilling use contraceptive precaution throughout trial ( postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Myelogenous Leukemia</keyword>
	<keyword>chronce</keyword>
	<keyword>Philadelphia Chromosome Positive</keyword>
	<keyword>Flumatinib</keyword>
</DOC>